Validation well worth waiting for
After Destiny’s December trading update that led with draft terms and exclusivity being agreed for the licensing of its lead product, NTCD-M3, Destiny has confirmed the signing of the transaction with US gastroenterology (GI) specialist Sebela Pharmaceuticals.In return for the exclusive North American rights, Destiny will receive up to $570m including upfront, development and sales-based milestone payments, plus royalties. This transaction not only provides Destiny significant validation for their lead product, but also helps its potential ex-US partners who should now see M3 as an asset that has been significantly de-risked.
Our fair value for Destiny for now remains unchanged at £251.2m or 345p per share. We shall revise our M3 model, Destiny’s financials including cash and share count after the result of the general meeting to approve the fundraising on 16 March 2023 and clarity on the Open Offer take-up.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.